Skip to content

    Lung Cancer Health Center

    Font Size
    A
    A
    A

    New Progress in Targeted Lung Cancer Therapy

    Researchers Report Positive Results With Drugs Matched to a Tumor's Molecular Traits
    By
    WebMD Health News
    Reviewed by Laura J. Martin, MD

    April 19, 2010 (Washington, D.C.) -- New research offers hope that people with lung cancer will live longer if drug therapy is guided by the molecular traits of tumors.

    "The goal is to match the correct drug with the right patient, based on the best tumor markers we have," says Roy Herbst, MD, of the University of Texas M.D. Anderson Cancer Center in Houston.

    So far, researchers have only shown that so-called targeted drugs seem to shrink tumors better if they are chosen based on tumors' specific molecular traits, or biomarkers.

    But there is a hint that these gains will someday translate into living longer, Herbst tells WebMD.

    Herbst led the mid-stage trial known as BATTLE, short for Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination. In the study, researchers tested four targeted drugs based on patients' biomarkers.

    After eight weeks, tumors shrank or stopped growing in 46% of the patients, all of whom had late-stage lung cancer. Typically, only about 30% of these patients would be expected to respond, Herbst says.

    Lung Cancer's Toll

    Lung cancer is the nation's No. 1 cancer killer, taking the lives of 160,000 Americans a year.

    Targeted therapies such as Herceptin and Gleevec have dramatically improved the survival of breast cancer and leukemia patients, but "we're in the dark ages of lung cancer treatment," says M.D. Anderson's Edwin Kim, MD. He presented the BATTLE findings at the annual meeting of the American Association for Cancer Research.

    The study involved 255 people with advanced non-small-cell lung cancer, the most common type of lung cancer.

    Until recently, there have been few treatment options; with chemotherapy, patients lived an average of only eight months from diagnosis.

    In the study, all the patients underwent biopsies so their tissue could be tested for biomarkers associated with non-small-cell lung cancer.

    Patients were given one of four targeted treatments: Tarceva, Zactima, Targretin, or Nexavar.

    The best results were seen with Nexavar, Kim says. Already approved for liver and kidney cancer, it targets a mutation in a gene called KRAS that is implicated in many cancers.

    Today on WebMD

    Xray analysis
    Do you know the myths from the facts?
    chest x-ray
    Get to know them.
     
    woman taking pills
    Tips to managing them.
    Lung cancer xray
    See it in pictures, plus read the facts.
     
    Lung Cancer Risks Myths and Facts
    SLIDESHOW
    Woman getting ct scan
    Article
     
    Improving Lung Cancer Survival Targeted Therapy
    VIDEO
    cancer fighting foods
    Article
     
    Lung Cancer Surprising Differences Between Sexes
    VIDEO
    Pets Improve Your Health
    SLIDESHOW
     
    Vitamin D
    SLIDESHOW
    Lung Cancer Surgery Options
    VIDEO